Company Profile
Assertio Stock Price, News & Catalysts
- Ticker:
- ASRT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
23.50 USD (+0.13%)
Close
Last updated: June 15, 2026
152M USD
Market cap
Why the stock is moving
Current closing-price context is not available for ASRT.
Company overview
Specialty Pharmaceutical Company
Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities.
Rolvedon Oncology Franchise
Rolvedon, or eflapegrastim-xnst, is a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection manifested by febrile neutropenia in adults receiving myelosuppressive anticancer therapy. It is the company's lead product and is promoted to both hospital systems and community oncology practices.
Sympazan Neurology Product
Sympazan is an oral film formulation of clobazam used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. The film adheres to the tongue and can serve patients who have difficulty swallowing conventional tablets or liquids.
Hospital and Pain Products
The remaining marketed portfolio includes INDOCIN formulations, SPRIX ketorolac nasal spray, and CAMBIA diclofenac oral solution. These products address hospital, acute-pain, migraine, and inflammatory-care settings, although they are less central to the company's current oncology-focused strategy.
Acquisition-Led Commercial Model
Assertio seeks approved or late-stage products that can be supported through its existing infrastructure. Centralized commercialization and portfolio integration allow the company to manage products across multiple specialty channels without operating a broad internal research platform.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Assertio (ASRT)?
Assertio (ASRT) most recently closed at 23.50 USD, a +0.13% move versus the previous session.
What is the market cap of Assertio (ASRT)?
Assertio currently has a market capitalization of 152M USD on BioPharmSignal.
What does Assertio do?
Specialty Pharmaceutical Company Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities. Rolvedon...
On which exchange is ASRT stock listed?
Assertio (ASRT) is associated with NASDAQ, United States, Biopharma.
What is Specialty?
Specialty Pharmaceutical Company Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care.
Which conditions is Assertio targeting with Specialty?
Assertio is associated with oncology, cancer therapeutics, neurology based on its company overview and current catalyst commentary.
What is Pharmaceutical?
Specialty Pharmaceutical Company Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care.
What is Assertio?
Specialty Pharmaceutical Company Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care.